BR112017006468A2 - anticorpo biespecífico, composição farmacêutica, kit, uso de uma combinação de um anticorpo biespecífico e método de tratamento de câncer - Google Patents

anticorpo biespecífico, composição farmacêutica, kit, uso de uma combinação de um anticorpo biespecífico e método de tratamento de câncer

Info

Publication number
BR112017006468A2
BR112017006468A2 BR112017006468A BR112017006468A BR112017006468A2 BR 112017006468 A2 BR112017006468 A2 BR 112017006468A2 BR 112017006468 A BR112017006468 A BR 112017006468A BR 112017006468 A BR112017006468 A BR 112017006468A BR 112017006468 A2 BR112017006468 A2 BR 112017006468A2
Authority
BR
Brazil
Prior art keywords
bispecific antibody
kit
combination
pharmaceutical composition
treatment method
Prior art date
Application number
BR112017006468A
Other languages
English (en)
Inventor
Wartha Katharina
Majety Meher
Krieter Oliver
Friess Thomas
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BR112017006468A2 publication Critical patent/BR112017006468A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

a presente invenção refere-se a anticorpos biespecíficos que compreendem pelo menos um local de ligação de antígenos específico para dr5 e pelo menos um local de ligação de antígenos específico para fap, anticorpos específicos para dr5 e, particularmente, a terapias de combinação que empregam esses anticorpos biespecíficos e um agente quimioterapêutico e o uso dessas terapias de combinação para o tratamento de câncer.
BR112017006468A 2014-10-08 2015-10-06 anticorpo biespecífico, composição farmacêutica, kit, uso de uma combinação de um anticorpo biespecífico e método de tratamento de câncer BR112017006468A2 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP14188176 2014-10-08
EP15151221 2015-01-15
EP15160231 2015-03-23
EP15179117 2015-07-30
PCT/EP2015/072974 WO2016055432A2 (en) 2014-10-08 2015-10-06 Combination therapy of bispecific antibodies specific for fap and dr5 and chemotherapeutic agents

Publications (1)

Publication Number Publication Date
BR112017006468A2 true BR112017006468A2 (pt) 2017-12-19

Family

ID=54249506

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017006468A BR112017006468A2 (pt) 2014-10-08 2015-10-06 anticorpo biespecífico, composição farmacêutica, kit, uso de uma combinação de um anticorpo biespecífico e método de tratamento de câncer

Country Status (14)

Country Link
US (1) US20180064808A1 (pt)
EP (1) EP3204412B1 (pt)
JP (2) JP6810687B2 (pt)
KR (1) KR20170063946A (pt)
CN (1) CN106999580B (pt)
AU (1) AU2015330087A1 (pt)
BR (1) BR112017006468A2 (pt)
CA (1) CA2962124A1 (pt)
IL (1) IL251203A0 (pt)
MX (1) MX2017004526A (pt)
RU (1) RU2017116020A (pt)
SG (1) SG11201702805TA (pt)
WO (1) WO2016055432A2 (pt)
ZA (1) ZA201702050B (pt)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
EP2417156B1 (en) 2009-04-07 2015-02-11 Roche Glycart AG Trivalent, bispecific antibodies
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
SG187746A1 (en) 2010-08-13 2013-03-28 Roche Glycart Ag Anti-fap antibodies and methods of use
WO2012025530A1 (en) 2010-08-24 2012-03-01 F. Hoffmann-La Roche Ag Bispecific antibodies comprising a disulfide stabilized - fv fragment
ES2549638T3 (es) 2011-02-28 2015-10-30 F. Hoffmann-La Roche Ag Proteínas de unión a antígeno
CN103403025B (zh) 2011-02-28 2016-10-12 弗·哈夫曼-拉罗切有限公司 单价抗原结合蛋白
WO2014001324A1 (en) 2012-06-27 2014-01-03 Hoffmann-La Roche Ag Method for selection and production of tailor-made highly selective and multi-specific targeting entities containing at least two different binding entities and uses thereof
RU2015100656A (ru) 2012-06-27 2016-08-20 Ф. Хоффманн-Ля Рош Аг Способ получения конъюгатов fc-фрагмента антитела, включающих по меньшей мере одну связывающую группировку, которая специфически связывается с мишенью, и их применения
MX2016003593A (es) 2013-10-11 2016-06-02 Hoffmann La Roche Anticuerpos de cadena ligera variable comun intercambiada de dominio multiespecifico.
EP3227332B1 (en) 2014-12-03 2019-11-06 F.Hoffmann-La Roche Ag Multispecific antibodies
US10689449B2 (en) 2015-01-20 2020-06-23 Igm Biosciences, Inc. Multimeric death domain-containing receptor-5 (DR5) antibodies and uses thereof
BR112018002570A2 (pt) 2015-10-02 2018-10-16 Hoffmann La Roche molécula de ligação ao antígeno biespecífica, anticorpo biespecífico, polinucleotídeos, anticorpo que se liga especificamente ao ox40, composição farmacêutica e método para inibir o crescimento de células tumorais em um indivíduo
RU2758007C2 (ru) 2016-06-30 2021-10-25 Онкорус, Инк. Доставка терапевтических полипептидов посредством псевдотипированных онколитических вирусов
JP7162592B2 (ja) 2016-12-14 2022-10-28 パーデュー・リサーチ・ファウンデイション 線維芽細胞活性化タンパク質（ｆａｐ）標的イメージングおよび治療
SG11201908127WA (en) 2017-03-10 2019-10-30 Hoffmann La Roche Method for producing multispecific antibodies
WO2019133847A1 (en) 2017-12-29 2019-07-04 Oncorus, Inc. Oncolytic viral delivery of therapeutic polypeptides
WO2020023502A1 (en) 2018-07-23 2020-01-30 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
SG11202108398YA (en) * 2019-02-01 2021-08-30 Novarock Biotherapeutics Ltd Anti-claudin 18 antibodies and methods of use thereof
WO2021151005A1 (en) * 2020-01-22 2021-07-29 Ansun Biopharma, Inc. Inhaled das181 to treat cancer in the lung

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080248046A1 (en) * 1997-03-17 2008-10-09 Human Genome Sciences, Inc. Death domain containing receptor 5
CN102574921B (zh) * 2009-09-29 2016-05-04 罗切格利卡特公司 双特异性死亡受体激动型抗体
SI2519543T1 (sl) * 2009-12-29 2016-08-31 Emergent Product Development Seattle, Llc Beljakovine, ki se vežejo s heterodimeri in njihova uporaba
SG187746A1 (en) * 2010-08-13 2013-03-28 Roche Glycart Ag Anti-fap antibodies and methods of use
UA118028C2 (uk) * 2013-04-03 2018-11-12 Рош Глікарт Аг Біспецифічне антитіло, специфічне щодо fap і dr5, антитіло, специфічне щодо dr5, і спосіб їх застосування
JP6618463B2 (ja) * 2013-05-07 2019-12-11 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 三量体型抗原結合分子

Also Published As

Publication number Publication date
CN106999580A (zh) 2017-08-01
EP3204412B1 (en) 2020-08-19
IL251203A0 (en) 2017-05-29
US20180064808A1 (en) 2018-03-08
SG11201702805TA (en) 2017-05-30
AU2015330087A1 (en) 2017-04-06
JP6810687B2 (ja) 2021-01-06
EP3204412A2 (en) 2017-08-16
RU2017116020A (ru) 2018-11-12
CA2962124A1 (en) 2016-04-14
WO2016055432A2 (en) 2016-04-14
RU2017116020A3 (pt) 2019-04-05
JP2021008476A (ja) 2021-01-28
ZA201702050B (en) 2018-05-30
WO2016055432A3 (en) 2016-06-02
KR20170063946A (ko) 2017-06-08
CN106999580B (zh) 2021-07-06
MX2017004526A (es) 2017-06-07
JP2018502822A (ja) 2018-02-01

Similar Documents

Publication Publication Date Title
BR112017006468A2 (pt) anticorpo biespecífico, composição farmacêutica, kit, uso de uma combinação de um anticorpo biespecífico e método de tratamento de câncer
BR112018003984A2 (pt) anticorpos
CO2018001149A2 (es) Anticuerpos monoclonales contra bcma
CO2018010458A2 (es) Composiciones y anticuerpos anti-tim-3
CU20170169A7 (es) Anticuerpos de factor xi
MX2018005720A (es) Anticuerpos pd-l1, fragmento de union al antigeno del mismo, y aplicacion medica de ello.
EA201500995A1 (ru) Биспецифические антитела, специфические в отношении fap и dr5, антитела, специфические в отношении dr5, и способы их применения
EA201891983A1 (ru) Комбинированная терапия антителами к cd73
CR20180013A (es) Anticuerpos anti-tau y métodos de uso.
CL2016000468A1 (es) Conjugados anti-dll3 (ligando3 tipo delta) manipulados y métodos de uso.
MX2017004311A (es) Anticuerpos del receptor del factor de necrosis tumoral inducido por glucocorticoide (gitr) y metodos de uso de los mismos.
GT201700284A (es) Terapias de combinación para enfermedades malignas hematológicas con anticuerpos anti-cd38 e inhibidores de survivina
BR112017016636A2 (pt) formulação líquida estável para anticorpos monoclonais
MX2016012124A (es) Anticuerpos contra glicopeptidos inmunogenicos, composicion que los comprende y usos de estos.
CU24533B1 (es) Anticuerpos o fragmentos de los mismos que se unen a linfopoyetina estromal tímica (tslp) y composiciones farmacéuticas de los mismos
BR112016030686A2 (pt) anticorpos anti tau humanizados
PH12017500002A1 (en) Anti-cdh6 antibody drug conjugates
EP3176181A4 (en) Anti-ctla4 monoclonal antibody or antigen binding fragment thereof, medicinal composition and use
BR112015030356A2 (pt) métodos de tratamento de uma taupatia
MX2019015738A (es) Regimen de dosificacion para anticuerpos anti-tim-3 y usos de los mismos.
PH12016502061A1 (en) Novel antii-rnf43 antibodies and methods of use
PH12016501366A1 (en) Novel anti-baff antibodies
CL2018001722A1 (es) Nuevos anticuerpos anti-mfi2 y métodos de uso (divisional solicitud 201700506)
CL2017002983A1 (es) Terapia combinada de un anticuerpo anti-cd-20 con un inhibidor de bcl-2 y un inhibidor de mdm2
EA201790475A1 (ru) Способы лечения системной красной волчанки с использованием доменного антитела против cd28

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]

Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO EM FUNCAO DA REVOGACAO DO ART. 229-C DA LEI NO 9.279, DE 1996, POR FORCA DA LEI NO 14.195, DE 2021

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2640 DE 10-08-2021 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.